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Summary box
What is already known about this subject?
 Ź Acute intestinal infection is a common condi-
tion in the UK; there are approximately 17 million 
cases each year, which result in one million GP 
consultations.
 Ź The treatments recommended for acute diar-
rhoea by the National Institute for Health and Care 
Excellence guidance are luid and nutritional man-
agement, with antidiarrhoeal (antimotility) drugs 
considered unnecessary and only advisable for 
speciied groups.
 Ź Oral intestinal adsorbents, such as Enterosgel, offer 
a safe drug-free alternative to treat the symptoms of 
diarrhoea but require further exploration.
What are the new indings?
 Ź Enterosgel treatment signiicantly reduced the du-
ration of diarrhoea in adults with patient-reported 
acute diarrhoea, compared with oral rehydration 
solution alone.
 Ź The irst randomised trial of Enterosgel use in adults 
with acute diarrhoea in the UK.
How might it impact on clinical practice in the 
foreseeable future?
 Ź This study provides data suggesting that Enterosgel 
can be used to reduce the duration of diarrhoea in 
acute cases and could be a safe over-the-counter 
self-treatment option, including vulnerable groups, 
such as children, where antidiarrhoeal drugs are 
not recommended. Thereby reducing the impact on 
healthcare resources in both primary and secondary 
care.
AbSTrACT
background Acute intestinal infections are common 
conditions causing high morbidity and mortality especially 
in the young and elderly, resulting in a signiicant burden 
on health service resources and the economy. Current 
National Institute for Health and Care Excellence guidance 
are luid and nutritional management; however, this does 
not reduce the duration of diarrhoea and the challenge 
of treating diarrhoea itself remains. We investigated the 
eficacy, tolerability and safety of intestinal adsorbent 
Enterosgel (polymethylsiloxane polyhydrate) compared 
with standard care in adults with acute diarrhoea.
Methods This was a randomised controlled trial enrolling 
105 subjects to receive the medical device Enterosgel up 
to six times daily for up to 8 days with standard care (oral 
rehydration solution), or standard care alone. The primary 
endpoint was the duration of diarrhoea (hours) from 
randomisation to irst non-loose stool in the Enterosgel 
versus control group.
results A total of 51 subjects were randomised into 
the Enterosgel group and 54 into the control group, after 
excluding missing data, the data from 43 subjects in 
each group were analysed. Duration of diarrhoea was 
signiicantly shorter in the Enterosgel group at 27 hours 
versus 39 hours in the control group (HR was 1.74 [95% 
CI 1.06 to 2.87]) (p=0.03). This yielded a number needed 
to treat value of 5. Enterosgel was well tolerated and safe 
with no serious adverse events. One serious diarrhoea-
related event resulting in hospitalisation was reported in 
the control group.
Conclusions Enterosgel treatment was associated with 
a signiicant reduction in the duration of diarrhoea in 
adults with patient-reported acute diarrhoea, compared 
with standard care. These indings support the role of 
Enterosgel in acute diarrhoea especially in vulnerable 
groups where rapid resolution of symptoms is required. 
Reduction in symptom duration could translate to less 
healthcare costs and socioeconomic burden.
Trial registration number ISRCTN20758708
IntroductIon
WHO and Unicef claim that there are approx-
imately two billion cases of diarrhoeal disease 
every year worldwide, and in children under 
5 years of age, 1.9 million die from diarrhoea 
each year, most often in developing countries. 
Annually, in the UK, there are 17 million 
cases and 1 million physician consultations 
attributed to acute infectious diarrhoea.1
Acute infectious diarrhoea is characterised 
by sudden onset diarrhoea, with or without 
vomiting. Most cases are due to an enteric 
virus, but some are caused by bacterial or 
protozoal infections.2 The illness usually 
resolves without treatment within days and 
is often managed at home without seeking 
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professional advice. However, it still poses a significant 
burden on health service resources and the economy 
with many patients and parents missing time from work 
and seeking advice from healthcare professionals in 
primary or secondary care.1 3 4 Current National Insti-
tute for Health and Care Excellence (NICE) guidance is 
fluid and nutritional management.1 3 However, standard 
rehydration management does not reduce the duration 
of diarrhoea5 and the challenge of treating diarrhoea 
itself remains. There is a need for treatments, which can 
decrease the duration of illness and reduce attendances 
to primary care or emergency departments.
Oral intestinal adsorbents, also called enterosorbents, 
are used in many countries for the treatment of diar-
rhoea.6 A meta-analysis found that diosmectite, a natural 
clay intestinal adsorbent, significantly decreased the 
duration of acute diarrhoea in comparison with placebo, 
although further studies were recommended.7 Several 
studies have suggested that Enterosgel, an intestinal 
adsorbent consisting of an organosilicon compound, 
polymethylsiloxane polyhydrate, could be effective in the 
treatment of gastrointestinal disorders.8–12
Enterosgel has been available in Europe as an over-the-
counter medical device since 2011. The performance 
and safety have been documented through clinical 
studies and postmarketing safety surveillance for over 30 
years. However, these studies have suffered from inherent 
shortcomings with regards to methodological design and 
reporting.
The aim of this randomised controlled study was to 
evaluate the efficacy, tolerability and safety of Enterosgel 
in the treatment of acute diarrhoea in adults in a real-life, 
primary care setting.
MaterIals and Methods
study design
This was a randomised, controlled, multicentre prag-
matic study to assess efficacy, tolerability and safety of 
Enterosgel in the treatment of acute diarrhoea in adults 
compared with standard care. In line with many medical 
device studies, the use of a placebo is rare, most studies 
compare to approved therapies. The specific gel-like 
formulation and organoleptic properties of Enterosgel 
are difficult to simulate in a placebo, which is both safe 
and has no impact on the study outcomes. Hence, this 
was a pragmatic study utilising patient-reported outcomes 
compared with NICE guidance standard of care.
Ten primary care practices participated to recruit 105 
subjects, randomised in 1:1 ratio into two treatment 
arms for an 8-day treatment phase. Randomisation was 
completed using a computer-based stratified permuted 
blocks randomisation tool in the electronic case report 
form (Sealed Envelope Ltd, London, UK). Patients 
completed a daily diary to record symptoms and bowel 
movements. Stool samples collected at screening visit 
were evaluated for the presence of rotavirus, norovirus 
and common diarrhoea causing bacteria.
eligibility criteria
Inclusion criteria included aged 18–70 years with a 
patient-reported episode of acute diarrhoea, defined 
as at least three watery stools within the last 48 hours. 
Subjects with other potential causes of diarrhoea, such as 
any underlying condition that could cause chronic diar-
rhoea (gastroduodenal ulcer, ulcerative colitis or Crohn’s 
disease), were excluded from the study. Additional exclu-
sions included use of antibiotics, blood in stools, known 
cancer of any localisation, pregnancy and history of intes-
tinal atony or clinically significant allergic reactions.
Interventions
Subjects randomised to the experimental group received 
Enterosgel (n=51) to be taken according to instruc-
tions dependent on stool frequency and consistency 
and standard care, that is, oral rehydration solution 
(ORS) for 6–8 days. Dosage was two tablespoons imme-
diately mixed in a glass of water, followed by one table-
spoon (or one sachet) 1–6 times per day for 7–8 days 
(see online supplementary appendix 1 for the complete 
dosage instructions). The control group (n=54) received 
standard treatment (ORS) only. Use of antidiarrhoeal 
medications, such as loperamide, was prohibited during 
the treatment phase.
Measures of clinical eficacy and safety
The primary efficacy endpoint was the duration of diar-
rhoea defined as the time (hours) from randomisation to 
first non-watery stool (soft or firm) based on bowel move-
ment data, recorded in the patient daily diary. Secondary 
efficacy endpoints included the duration of diarrhoea 
defined as the time (hours) from randomisation to 
last watery stool, percentage of patients with diarrhoea 
resolved on day 3 (ie, first soft/firm stool recorded on 
day 0–3), stool frequency defined as average number of 
stools/day from randomisation to first soft or firm stool 
and duration (days) of nausea, vomiting, fever defined 
as ≥38°C and abdominal pain. A subgroup analysis was 
conducted in subjects whose stool samples were posi-
tive for an infectious agent. The tolerance and safety of 
Enterosgel were assessed via adverse events (AEs) and 
the percentage of patients with diarrhoea-related compli-
cations resulting in hospitalisation, accident and emer-
gency visit, nurse/GP home visit or unscheduled visit to 
the medical practice.
sample size calculation
The sample size calculation was based on demonstrating 
superiority of the interventional group on the primary 
outcome. Power was calculated for a continuous outcome 
superiority trial, assuming a SD for the duration of diar-
rhoea of 32 hours in line with previous studies.13 14 To 
detect an average decrease of 24 hours in the inter-
ventional group compared with the control group, 36 
subjects in each group were required for 90% power to 
demonstrate superiority at 5% significance. Accounting 
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Figure 1 CONSORT low diagram of the randomised controlled trial of adults with acute diarrhoea. After 226 were assessed 
for eligibility, 105 were randomised to either the control group or the intervention group receiving Enterosgel. 86 subjects 
completed the study and were analysed.
for a combined subject withdrawal of 30%, 52 subjects 
were required per arm.
statistical analysis
Analyses were performed using SPSS V.25 and STATA/
SE V.14.0. The baseline characteristics of the groups were 
summarised as mean (SD) and median (IQR) by trial 
arm.
Primary analysis was conducted on an intention-to-treat 
basis. For the primary outcome, unadjusted and adjusted 
(baseline characteristics [age and gender], duration of 
diarrhoea before randomisation, symptoms, use of medi-
cation at baseline and study site), Cox regression was used 
to compare groups and the time (hours) from randomis-
ation to first non-watery stool (soft or firm). The number 
needed to treat was calculated.
For the secondary outcomes, continuous data were 
compared using independent t-tests or Mann-Whitney U 
test (MW). Analysis of covariance (ANCOVA) was used 
to adjust for baseline characteristics. Categorical data 
were compared initially using χ2 or Fisher’s exact test and 
adjusted logistic regression models with ORs and 95% 
CIs. A p value of <0.05 was considered to indicate statis-
tical significance. Safety analysis included all subjects who 
were randomised to the study and was based on the treat-
ment received.
results
Participants
The study CONSORT flow diagram (figure 1) shows the 
progress through the parallel randomised trial. A total 
of 105 adults were randomised between January 2017 
and June 2018, 51 subjects were treated with Enterosgel 
and ORS, and 53 subjects in the control group with ORS 
alone (one subject was withdrawn). Forty-three subjects 
from each group completed the 8-day study: 8 subjects in 
the Enterosgel group discontinued and 10 in the control 
group. The reasons for discontinuation were: subjects did 
not return diary (n=6), were lost to follow-up (n=10) or 
withdrew (n=2).
The baseline characteristics were generally comparable 
between the treatment groups (table 1). The Enterosgel 
group had longer diarrhoea duration prior to randomis-
ation; however, this was based on a self-reported time so 
may have recall bias. The perceived difference was deter-
mined not to be significantly different between groups 
(MW, p=0.398) and was not significant in the fully adjusted 
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Table 1 Participant demographics and baseline data summarised by trial arm as analysed (ITT)
Variable Enterosgel (n=43) Control (n=43)
Age in years, mean (SD) 44.0 (14.2) 43.3 (14.5)
Age in years, median (IQR) 44 (32–55) 46 (31–56)
Sex: male, n (%) 22 (51) 22 (51)
Ethnicity, n (%) 
  White 41 (95) 39 (91)
  Asian British 0 (0) 3 (7)
  Black/African/Caribbean/Black British 0 (0) 1 (2)
  Mixed 1 (2) 0 (0)
  Other 1 (2) 0 (0)
Diarrhoea duration in hours*, mean (SD) 138.6 (138.3) 115.9 (139.5)
Diarrhoea duration in hours*, median (IQR) 96 (41–186) 77 (50–134)
Symptoms†, n (%) 
  Nausea 21 (50) 21 (49)
  Vomiting 10 (24) 12 (28)
  Fever (≥38°C) 7 (16) 21 (49)
  Abdominal pain 37 (86) 30 (70)
Potential sources of infection, n (%) 
  Travel 9 (21) 6 (14)
  Other contact 6 (14) 8 (19)
  Food poisoning 7 (17) 4 (9)
  Use of medication‡, n (%) 9 (21) 7 (16)
Listing for each group: age, sex, ethnicity, diarrhoea duration prior to randomisation (hours), symptoms (experienced prior to randomisation), potential sources of 
infection and use of any medication/treatment for the diarrhoea episode prior to randomisation.
*Duration of diarrhoea symptoms prior to randomisation (hours).
†Experienced prior to randomisation.
‡Use of any medication/treatment for the diarrhoea episode prior to randomisation.
ITT, intention-to-treat.
Table 2 Adjusted Cox regression models for the time (hours) from randomisation to irst non-watery stool (soft or irm)
Fully adjusted model Reduced model
Variable HR (95% CI) P value HR (95% CI) P value
  Group (Enterosgel) 1.560 (0.881 to 2.764) 0.127 1.737 (1.055 to 2.859) 0.030
  Age 1.016 (0.993 to 1.040) 0.163
  Gender (female) 0.756 (0.429 to 1.331) 0.332
  Site (10 sites)* 0.129
  Duration of diarrhoea† 1.001 (0.999 to 1.003) 0.352
  Use of medications at baseline (No) 2.253 (1.036 to 4.897) 0.040 1.797 (0.942 to 3.429) 0.075
  Nausea at baseline (No) 0.598 (0.322 to 1.109) 0.103
  Vomiting at baseline (No) 0.673 (0.351 to 1.291) 0.234
  Fever at baseline (No) 1.887 (0.968 to 3.68) 0.062
  Abdominal pain at baseline (No) 2.535 (1.135 to 5.661) 0.023 1.799 (0.999 to 3.242) 0.050
*Individual site data not shown.
†Duration of diarrhoea symptoms prior to randomisation.
model (p=0.352) for the primary outcome (table 2). The 
Enterosgel group had a lower proportion of participants 
with fever at baseline (16% vs 49%) but a higher propor-
tion of abdominal pain (86% vs 70%) and a higher base-
line reported use of medications for the current diarrhoea 
episode prior to randomisation (21% vs 16%).
For the analysis of detected stool pathogen, there 
was missing data for five subjects as they did not return 
their stool sample for analysis. Pathogen was detected 
in 20 subjects (7 Enterosgel and 13 control) and no 
pathogen was detected in 62 subjects (35 Enterosgel and 
27 control).
duration of diarrhoea (to irst non-watery stool)
The primary outcome was the duration of diarrhoea 
defined as the time in hours from subject randomisation 
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Figure 2 Survival curve showing the time in hours to 
irst non-watery stool (soft or irm) from randomisation by 
treatment group.
Table 3 Summary statistics for duration (days) from 
randomisation to the last patient reported symptoms of 
nausea, vomiting, fever, deined as ≥38°C, and abdominal 
pain, for each treatment group (n, mean [SD], median [IQR] 
and min–max)
Group N Mean (SD)
Median 
(IQR) Min–Max
Nausea 
  Control 13 2.1 (2.5) 1 (0–3) 0–8
  Enterosgel 12 2.2 (2.4) 1 (1–4) 0–8
Vomiting 
  Control 4 0.8 (1.0) 1 (0–2) 0–2
  Enterosgel 4 0.5 (0.6) 1 (0–1) 0–1
Fever 
  Control 21 3.8 (2.0) 4 (3–5) 0–7
  Enterosgel 26 3.0 (2.6) 2 (1–5) 0–8
Abdominal pain
  Control 9 0.2 (0.4) 0 (0–0) 0–1
  Enterosgel 1 0.0 (0.0) 0 (0-0) 0
to first non-watery stool. It was not possible to derive 
the duration of diarrhoea for nine participants (nine 
control and seven Enterosgel) due to non-completion of 
the diary. Two patients had diary data missing and were 
censored at their last recorded stool. The mean time 
from randomisation to first non-watery stool (soft or 
firm) was shorter in the Enterosgel group 27.1 (se: 4.7) 
hours versus 38.9 (se: 6.3) hours in the control group 
(figure 2). The adjusted Cox regression models are 
presented in table 2 and retaining pain and use of medi-
cations at baseline gave an HR of 1.74 (95% CI 1.055 to 
2.859, p=0.030), which was statistically significant. This 
corresponds to a 64% chance of the Enterosgel subject's 
diarrhoea resolving first.
The percentage of subjects in the control group whose 
diarrhoea had resolved at 12, 24 and 36 hours was 29%, 
55% and 57%, compared with Enterosgel group of 39%, 
64% and 72%, respectively. The number needed to treat, 
so that diarrhoea was resolved at 12 hours was estimated 
at 4.98 (2.79–47.43), at 24 hours as 6.26 (3.80 to 52.69) 
and at 36 hours as 6.51 (3.97 to 54.34).
duration of diarrhoea (to last liquid stool)
As a secondary outcome, we analysed the duration of 
diarrhoea defined as the time in hours from subject 
randomisation to the last liquid stool. For 77 patients 
with data, 44 subjects (57%) reported having at least one 
liquid stool after randomisation; 24/41 (59%) controls 
and 20/36 (56%) in the Enterosgel group. There was 
a non-significant shorter diarrhoea duration until last 
liquid stool in the Enterosgel group (25.3 hours vs 38.4 
hours) than the control group (p=0.20). The ANCOVA 
model, to adjust for baseline characteristics (age and 
gender), duration of diarrhoea, symptoms and use of 
medication at baseline and study site, revealed no signif-
icant differences between groups (p=0.08). The beta 
value was 19.44 (SE 10.70), which indicates that the 
control group had on average 19.44 hours longer until 
last liquid stool.
stool frequency
There was no significant difference between groups in 
the total number of stools until diarrhoea resolved (MW, 
p=0.84), within the Enterosgel group, the mean number 
of stools was 3.3 (SD 6.2) and in the control group 3.5 
(SD 5.6). Likewise, the mean number of stools per day 
from randomisation to first soft or firm stool showed no 
significant difference between groups (MW, p=0.83). The 
Enterosgel group had 1.8 (SD 2.3) stools per day and the 
control group 1.3 (1.6) (p=0.83).
duration of other symptoms
The duration of other symptoms is summarised in 
table 3. Only subjects who reported to have experienced 
the symptom prior to randomisation on the day of 
screening visit were included in this data set. There were 
no significant differences between groups for the dura-
tion of nausea (MW, p=0.85), vomiting (MW, p=0.89), 
fever (MW, p=0.15) or abdominal pain (MW, p=0.80), 
where the duration was determined based on the day 
on which the symptom was last recorded in the patient 
diary.
stool sample pathogens
A total of 20 subjects had a pathogen detected (7 
Enterosgel and 13 control), the HR for the primary 
outcome was 1.67 (95% CI 0.63 to 4.35, p=0.30) but the 
sample size was underpowered to derive any clinically 
meaningful interpretation. The most common pathogen 
detected was Campylobacter, which was detected in the 
stools of sixteen subjects, norovirus was detected in four 
subjects, Giardia lamblia in two subjects and there was one 
case of Salmonella enterica and Cryptosporidium.
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analysis of aes
Enterosgel treatment was well tolerated, the total number 
of AEs reported was higher in the control group (n=18) 
than in the Enterosgel group (n=13). AEs were reported 
by 8 control subjects and 10 Enterosgel subjects. Most 
AEs were mild and similar in the two treatment groups, 
but the control group reported more moderate AE (3 
vs 1). In the Enterosgel group, subjects reported head-
ache (four cases), mucous in nose and throat, constipa-
tion (two cases), nausea (two cases), bloating, burping, 
powdery taste in mouth and indigestion. The control 
group reported similar AEs, headache (three cases), 
abdominal pain (four cases), flatulence (one case), 
fatigue, back pain, fever, dry tongue, and constipation. 
All AEs could be related to the underlining condition.
One serious AE (SAE) was recorded, this was a diar-
rhoea-related complication (sepsis) in a control subject, 
which resulted in hospitalisation (1.9% of patients). No 
SAEs or diarrhoea-related complications resulting in 
hospitalisation were reported in the Enterosgel group. 
No patients in either group had an unscheduled visit to 
their GP where the reason for visit was an intestinal AE.
dIscussIon
The study provides evidence that Enterosgel reduces 
diarrhoea duration in patients with acute diarrhoea 
of infectious or non-infectious aetiology. Primary 
outcome of duration of diarrhoea to first non-watery 
stool showed a statistically significant decrease (p=0.03) 
in the Enterosgel group, which corresponds to a 64% 
chance of the Enterosgel subject's diarrhoea resolving 
first compared with standard therapy alone. The propor-
tion whose diarrhoea had resolved at 12, 24 and 36 hours 
was comparatively higher in the Enterosgel group at 
each time interval. As all efficacy and safety data were 
recorded in patient diaries, the study outcomes were not 
subject to assessor bias and outcomes were standardised 
to minimise any bias resulting from the subjects being 
unblinded. The number needed to treat, for resolution 
of diarrhoea at 12 hours, was estimated at 4.98, which 
equates to one extra patient with diarrhoea resolved at 
12 hours for every 4.98 patients treated with Enterosgel.
These findings are consistent with previously published 
data from three studies of acute intestinal infection in 
children.8–10 Diarrhoea resolved more rapidly in patients 
treated with Enterosgel compared with standard care8 or 
antibiotic and standard care.9 In a randomised prospec-
tive open comparative study of the intestinal adsorbents, 
Enterosgel, Diosmectite and Kaolin, there were no statis-
tically significant differences between the groups for the 
duration of diarrhoea. Other studies have shown that 
Enterosgel use in newborns with rotavirus infection can 
reduce the duration of diarrhoea by 1.4 times,11 and 
in antibiotic-associated diarrhoea in adults, result in a 
decrease in length of hospital stay.12
The secondary outcome, safety and tolerability, of 
Enterosgel was confirmed, as there were no SAE or 
serious adverse device effect in the Enterosgel arm. 
Furthermore, none of the patients had an unscheduled 
visit to their General Practitioner (GP) where the reason 
for visit was an AE related to intestinal infection. There 
was one control group patient that had a serious adverse 
diarrhoea-related complication that resulted in hospi-
talisation. There were five transient mild AEs possibly 
relating to the investigational device. These included 
constipation and nausea, known infrequent possible side 
effects which are currently listed in the Instruction for 
Use, whereas burping and indigestion have not previ-
ously been recorded as side effects and could be linked 
to the underlying condition.
There were no statistically significant differences 
between groups for secondary outcomes, that is, the dura-
tion of diarrhoea defined as the time until the last liquid 
stool, percentage of patients with diarrhoea resolved 
from 12 hours to day 3, stool frequency or duration of 
nausea, vomiting, fever or abdominal pain. However, 
there was a trend towards shorter duration in the resolu-
tion of diarrhoea in the Enterosgel group (25.3 hours vs 
38.4 hours), although this was not statistically significant 
(p=0.20), possibly due to being underpowered.
Enterosgel is an oral adsorbent, typical of several 
materials, such as charcoal, clay, silica-based materials 
and dietary fibres used to treat poisoning and different 
diseases, such as diarrhoea.15 The therapeutic mode of 
action of Enterosgel may occur through the adsorption 
of bacterial toxins known causes of diarrhoea followed 
by complete removal from the body. In-vitro studies 
have demonstrated Enterosgel’s capacity for Escherichia 
coli endotoxin, bacterial enterotoxins Clostridium difficile 
toxin A and B, and Shigella toxin16 and staphylococcal 
enterotoxins A and B.17 Other mechanisms may include 
creation of an adverse environment for pathogenic micro-
organisms,18 immunocorrection19 and inhibiting viral 
replication,20 primarily through physical adsorption. A 
possible benefit of Enterosgel use is in reducing the level 
of complications of diarrhoea-related bacterial infection. 
Prospective studies have shown that up to 36% of intes-
tinal infections can be followed by prolonged post-in-
fective irritable bowel syndrome.21 Thus, treatment with 
Enterosgel could offer a reduction in secondary care 
admissions, and financial burden on the health service. 
However, a large-scale study is recommended with health 
economics evaluation before introducing Enterosgel 
onto the UK’s drug tariff.
In young children with acute infectious diarrhoea, it is 
important to provide rehydration therapy. Although ORS 
can alleviate dehydration, it has no effect on the dura-
tion of diarrhoea or abdominal pain.5 Thus, Enterosgel 
may have an additional benefit, especially in vulnerable 
groups; for example, children and elderly or immuno-
compromised/renal dialysis/receiving chemotherapy 
where more rapid resolution of diarrhoeal symptoms 
could have a beneficial impact on health.
This study had limitations namely that the median 
duration of diarrhoea prior to randomisation was 86 
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hours (min–max: 7–690) as there was no upper limit in 
the exclusion criteria. The Department of Health guid-
ance for adults with acute diarrhoea is to only visit their 
GP if they have diarrhoea for more than 7 days. The 
delay could have impacted on the measured efficacy of 
the treatment. The secondary outcome diarrhoea dura-
tion until the last liquid stool was only available for those 
patients who had a liquid stool after randomisation and 
resulted in an underpowered sample size, which may 
have contributed to the non-significance. These may have 
been avoided by capturing patients at an earlier stage; 
for example, from pharmacies, before patients made 
an appointment with their GP. This study was not place-
bo-controlled, although it was compared with current 
recommended standard of care, which can be justified 
for studies wanting to provide evidence of improved effi-
cacy of a new therapy over an existing therapy.22 More-
over, outcomes were standardised to minimise any bias 
and based on patient-reported outcomes.
In conclusion, a course of Enterosgel treatment was 
associated with a significant reduction in the duration 
of diarrhoea in adults with a patient-reported episode 
of acute diarrhoea, compared with ORS alone. As these 
patients were mainly from the working population, the 
indirect benefit from this rapid resolution of symptoms 
could translate to prevention of further complications, 
less healthcare visits with reduced absence from work 
and a reduction in the economic burden on society. 
Future work will need to define Enterosgel’s efficacy in 
acute diarrhoea of infectious or non-infectious aetiology 
in different healthcare settings and patient populations. 
This will help to inform our understanding of oral adsor-
bents and may have wider implications regarding their 
use as an alternative to antibiotics and in conditions, such 
as chronic diarrhoea, and other diseases related to the 
gastrointestinal tract.
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